Atopic dermatitis patients treated with dupilumab and not achieving investigator’s global assessment 0 or 1 demonstrated clinically meaningful and significant improvements in signs, symptoms, and quality of life: A post hoc analysis of LIBERTY AD SOLO - 03/08/18
Eric L. Simpson, Department of Dermatology, Oregon Health and Science University; Jonathan I. Silverberg, Northwestern University Feinberg School of Medicine; Diamant Thaci, University of Lubeck; Sebastien Barbarot, Service de Dermatologie, Centre Hospitalier Universitaire (CHU) de Nantes; Jerry Bagel, Psoriasis Treatment Center of Central New Jersey; Zhen Chen, Regenereon Pharmaceuticals; Jingdong Chao, Regeneron Pharmaceuticals; Neil M.H. Grahm, Regeneron Pharmaceuticals; Gianluca Pirozzi, Sanofi; Marius Ardeleanu, Regeneron Pharmaceuticals.
Le texte complet de cet article est disponible en PDF. Commercial support: Sanofi and Regeneron Pharmaceuticals, Inc. ClinicalTrials.gov identifiers: NCT02277743 (LIBERTY AD SOLO 1) and NCT02277769 (LIBERTY AD SOLO 2). Medical writing/editorial support provided by Ferdinando Giacco, PhD, Excerpta Medica. |
Vol 79 - N° 3S1
P. AB51 - septembre 2018 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?